GSK has bolstered its pipeline of small interfering RNA (siRNA) drugs by licensing a potentially first-in-class therapy from China's Suzhou Siran Bio (SiranBio). The therapy, codenamed SA030, is a ...

Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its decision to bet big on Arrowhead Pharmaceuticals’ pipeline.

Hongtao Liu, Shujie Yu, Wenjia Xu, Jian Xu. Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arterioscler ...

Does the universe notice that we're paying attention to a quantum experiment? The answer goes against everything we thought we knew. When you purchase through links on our site, we may earn an ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

We discovered that two mitotic regulators, BuGZ and Bub3, involved in splicing regulation during interphase Overall design: 8 samples from primary Human foreskin fibroblast cells (HFFs) , 12 samples ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

In August 1971, at the tail end of summer break, the Stanford psychology professor Philip Zimbardo recruited two dozen male college students for what was advertised as “a psychological study of prison ...

In 1971, Stanford University psychologist Philip Zimbardo conducted a notorious experiment in which he randomly divided college students into two groups, guards and prisoners, and set them loose in a ...

siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...